TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01578239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Description: In the experimental arm, 30 mg Octreotide LAR treatment was given to the participants until the end of study for symptom control purpose, unless the participant progressed or died.~In the active comparator arm, 60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR
Description: In the experimental arm, 30 mg Octreotide LAR treatment was given to the participants until the end of study for symptom control purpose, unless the participant progressed or died.~In the active comparator arm, 60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA0-Tyr3-Octreotate
Description: Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
Study: NCT00671281

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Oral form, three times a day, 3 days before/day of/6 days after surgery
Study: NCT00006105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study: NCT00759759

Intervention type: DRUG
Group type: OTHER
Intervention: morphine sulfate sustained-release capsules
Description: 1 x 200 mg, single-dose capsule
Study: NCT01842438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: psychosexual intervention
Description: 6 session manualised intervention, This manual-based family-relational-psychosexual support was based on systemic principles combined with techniques from sex therapy, i.e. sensate focus. The manual offered an intermediate level of specificity, enabling practitioners to use their own therapeutic style and take some lead from the couple while meeting the objectives of the intervention. Specialist training in delivery of the intervention was provided to practitioners holding accredited counselling or psychotherapy qualifications. Practitioners engaged in routine clinical supervision with one additional team supervision session offered by one of the practitioners
Study: NCT02694822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1884
Description: anti-CTLA-4 antibody
Study: NCT02644954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg twice daily given in the intervention arm to patients of moderate psoriasis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug twice daily given in the intervention arm to patients of moderate psoriasis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Coal tar
Description: Topical coal tar to be applied once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Coal tar
Description: Topical coal tar to be applied once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical calcipotriol
Description: Topical calcipotriol to be applied once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical calcipotriol
Description: Topical calcipotriol to be applied once daily
Study: NCT01828502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants in both groups will receive education by the EPA on the danger of exposure to secondhand smoke and how exposure can be prevented.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Participants in both groups will receive education by the EPA on the danger of exposure to secondhand smoke and how exposure can be prevented.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cotinine Education
Description: Those randomized to the active intervention will also be provided with education utilizing the cotinine test strip in conjunction with the education from the EPA.
Study: NCT00759759

Intervention type: DRUG
Group type: OTHER
Intervention: morphine sulfate sustained-release capsules
Description: 1 x 200 mg, single-dose capsule

Intervention type: DRUG
Group type: OTHER
Intervention: KADIAN (morphine sulfate sustained-release) capsules
Description: 2 x 100 mg, single-dose capsule

Intervention type: DRUG
Group type: OTHER
Intervention: KADIAN (morphine sulfate sustained-release) capsules
Description: 2 x 100 mg, single-dose capsule
Study: NCT02426827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Study: NCT05161559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Etching with phosphoric acid gel (3M ESPE, St. Paul, MN, USA)
Description: Etching enamel surface using phosphoric acid gel (3M ESPE, St. Paul, MN, USA)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive (Kuraray, Tokyo, Japan)
Description: No Etching enamel surface using phosphoric acid (self-etch technique) (Kuraray, Tokyo, Japan)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive (Kuraray, Tokyo, Japan)
Description: No Etching enamel surface using phosphoric acid (self-etch technique) (Kuraray, Tokyo, Japan)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemical bond adhesive (GC, Corporation, Tokyo, Japan)
Description: Chemical bond with hydroxyapatite crystals of Enamel (GC, Corporation, Tokyo, Japan)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemical bond adhesive (GC, Corporation, Tokyo, Japan)
Description: Chemical bond with hydroxyapatite crystals of Enamel (GC, Corporation, Tokyo, Japan)
Study: NCT03283007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
Study: NCT03850561

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10 200
Description: Coenzyme Q10 200 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10 400
Description: Coenzyme Q10 400 mg/day
Study: NCT03525327

Intervention type: OTHER
Intervention: Line Dance Class
Description: Line or party dances to be taught will include:~Electric Slide (Mainland USA)Hukilau (Hawaii)Cupid Shuffle (Mainland USA)Poco Poco (Philippines)Cha Cha Slide (Mainland USA)Tush Push (Mainland USA)Trojan Crawl (Mainland USA)Wobble (Mainland USA)Goyang Maumere (Indonesia)
Study: NCT01551394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: 20 mg/kg every 8 hours (every 12 hours in the youngest age group: \< 32 weeks GA and \< 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes. Treatment duration is 11 ± 3 days.
Study: NCT03277287

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Description: Fractional CO2 laser will be applied in cleft lip scar to assess and evaluate the later appearance of the scar

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Description: Fractional CO2 laser will be applied in cleft lip scar to assess and evaluate the later appearance of the scar
Study: NCT01156753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-011
Description: CDX-011 (1.88 mg/kg) administered as an intravenous infusion on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice chemotherapy
Description: Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Albumin-bound paclitaxel, Doxorubicin HCL, Liposomal doxorubicin, Ixabepilone and Eribulin.
Study: NCT01952340

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: Milled flaxseed

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Wheat germ/wheat bran and mixed dietary oils
Study: NCT03792594

Intervention type: OTHER
Intervention: arthroscopic repair with bone marrow concentration
Description: arthroscopic repair with bone marrow concentration

Intervention type: OTHER
Intervention: arthroscopic repair
Description: arthroscopic repair only
Study: NCT01782131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: POS IV: Day 1: 300 mg BID Day 2-84: 300 mg QD POS oral: Day 1: 300 mg BID Day 2-84: 300 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: VOR IV: Day 1: 6 mg/kg per body weight administered BID Day 2-84: 4 mg/kg per body weight administered BID VOR oral: Day 1: 300 mg BID Day 2-84: 200 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo received for Posaconazole (IV and oral) or Voriconazole (oral)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo received for Posaconazole (IV and oral) or Voriconazole (oral)
Study: NCT01551394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin + gentamicin or cefotaxime + gentamicin
Description: Ampicillin:~Neonates below 7 days: 50mg/kg every 12 hours Neonates 7-21 days: 50mg/kg every 8 hours Neonates and Infants from day 22 on: 50mg/kg every 6 hours~Gentamicin:~Neonates less than 32 weeks of corrected age: 5mg/kg every 36 hours Neonates 32 weeks and over of corrected age: 5mg/kg every 24 hours (pre-dose ('trough') concentrations should be less than 2mg/l) Infants over 28 days of postnatal age: once daily dose: initially 5-7mg/kg, then adjust according to serum-gentamicin concentration (pre-dose ('trough') concentrations should be less than 1mg/l)~Cefotaxime:~Neonates below 7 days of PNA: 50mg/kg every 12 hours Neonates and infants from day 7 of PNA: 50mg/kg every 8 hours Treatment duration is 11 ± 3 days.
Study: NCT01115699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Active 10 Hz rTMS will be applied to the left dorsolateral prefrontal cortex (L-DLPFC) with an intensity of 120% motor threshold. The L-DLPFC location is defined as that area 5 cm anterior to the motor cortex for activation of abductor pollicis brevis. Subjects will receive a total of 3000 stimuli per session. The TMS trains are 4 seconds on and 26 seconds off for a total of 37 1/2 minutes. Treatment will occur 5 days per week for up to six weeks. Subjects will be monitored during rTMS for any side effects or adverse events.
Study: NCT03939403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Time of administration of Corifollitropin Alfa
Description: The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The control grup will receive the treatment on the 5th day after the cessation of hormonal contraceptive use. The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The intervention grup will receive the treatment on the 7th day after the cessation of hormonal contraceptive use.
Study: NCT00817869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New flooring
Description: 8.3mm thick vinyl floor covering with foam backing, manufactured by Tarkett and installed by Tyndale Flooring Ltd.
Study: NCT01910597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBG
Study: NCT01067989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)
Description: 1. Cyclophosphamide Tab. 50mg, 1x1/day, continuously.~2. Capecitabine Tab. 500mg, 1+2/day, continuously.~3. Methotrexate Tab. 2.5mg, 1x2/day, 2 days every week.~4. Celecoxib Tab. 200mg, 1x2/day, continuously.~5. Pamidronate I.V. 90mg, every 4 weeks; or Zoledronate I.V. 4mg, every 4 weeks)
Study: NCT02170142

Intervention type: DEVICE
Intervention: MRI
Description: non-invasive MRI techniques (DTI) and (ASL) will be used to assess normal brain development. DTI is capable of invasively delineating macroscopic anatomic components with high contrast and revealing structures at the microscopic level. ASL is capable of measuring cerebral blood flow and cerebral metabolic rate of oxygen.
Study: NCT03159988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7)
Description: Angiotensin-(1-7) 100mcg/kg/day for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Training
Description: 50% of the treatment arm will receive 2 session per week for 2 weeks of memory training
Study: NCT00893867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-b99
Description: 1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
Study: NCT06289335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline solution
Description: 20 mL of saline

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: saline solution
Description: 20 mL of saline
Study: NCT02946619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulation Condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced self-Regulation Condition
Study: NCT01508572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab-IRDye800CW
Description: In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
Study: NCT00355680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green Laser (Aurolas, Aurolab)
Description: Green laser developed by Aurolab

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Green Laser (Iridex)
Description: Already available green laser
Study: NCT04896918

Intervention type: BEHAVIORAL
Intervention: Tobacco use
Study: NCT04618315

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aids
Description: Receiver-in-the-ear hearing aids.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aids
Description: Receiver-in-the-ear hearing aids.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aids
Description: Receiver-in-the-ear hearing aids.
Study: NCT02428634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSIE13
Description: The Program SI! is implemented from 1st to 3rd grade of Elementary. A total of 40 hours of intervention on 1st and 2nd grade and 30 hours on 3rd grade has been established as the minimum intervention per year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSIE13
Description: The Program SI! is implemented from 1st to 3rd grade of Elementary. A total of 40 hours of intervention on 1st and 2nd grade and 30 hours on 3rd grade has been established as the minimum intervention per year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSIE46
Description: The Program SI! is implemented from 4th to 6th grade of Elementary. A total of 30 hours of intervention has been established as the minimum intervention per year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSIE46
Description: The Program SI! is implemented from 4th to 6th grade of Elementary. A total of 30 hours of intervention has been established as the minimum intervention per year.
Study: NCT04828629

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic tests
Description: Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, co-morbidities, results of selected laboratory tests, lung imaging (X-ray or computed tomography) selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, body mass analysis.
Study: NCT01408407

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aveeno cream
Description: Apply cream on irradiated area twice a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aveeno cream
Description: Apply cream on irradiated area twice a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alkagin paste
Description: Apply Alkagin paste three times a day.
Study: NCT03231709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trelagliptin
Description: Trelagliptin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trelagliptin
Description: Trelagliptin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets
Study: NCT03162016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplants
Description: Transplant of palatine tissue and transplant of connective tissue Mucoderm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transplants
Description: Transplant of palatine tissue and transplant of connective tissue Mucoderm
Study: NCT01266473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy for Airway Clearance
Study: NCT00334828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eritoran tetrasodium
Description: Intravenous infusion at a total dose of 105 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo; intravenous infusion.
Study: NCT03658356

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Video instructions
Description: Pregnant patient will watch her video explaining how to collect a urine sample for asymptomatic bacteriuria determination.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video instructions
Description: Pregnant patient will watch her video explaining how to collect a urine sample for asymptomatic bacteriuria determination.
Study: NCT00133094

Intervention type: DRUG
Group type: OTHER
Intervention: Simvastin

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Computer-based decision support technology
Study: NCT04509752

Intervention type: OTHER
Intervention: Survey
Description: An online survey will be sent to each clinic to answer the survey questions.
Study: NCT03679845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Sarilumab is an IL-6 monoclonal antibody that has shown to be potentially important in the creation of sclerosis in SSc.
Study: NCT00881452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CM-AT
Description: Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single unit dose powder of non-active substance administered 3 times per day for 90 days
Study: NCT03039205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 600 mg loading dose + 75 mg q.d. for 7 to 9 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 600 mg loading dose + 75 mg q.d. for 7 to 9 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 180 mg loading dose + 90 mg b.i.d. for 7 to 9 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 180 mg loading dose + 90 mg b.i.d. for 7 to 9 days
Study: NCT04372888

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: choice decision frame
Description: active choice for genetic testing

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: choice decision frame
Description: active choice for genetic testing

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: opt-in decision frame
Description: gain frame for genetic testing

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: opt-in decision frame
Description: gain frame for genetic testing

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: opt-out decision frame
Description: loss frame for genetic testing

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: opt-out decision frame
Description: loss frame for genetic testing

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: enhanced choice (context) decision frame
Description: consequences of genetic testing

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: enhanced choice (context) decision frame
Description: consequences of genetic testing

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: enhanced choice (norms) decision frame
Description: social norms for genetic testing

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: enhanced choice (norms) decision frame
Description: social norms for genetic testing

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: enhanced choice (affect) decision frame
Description: commitments for genetic testing

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: enhanced choice (affect) decision frame
Description: commitments for genetic testing
Study: NCT00975884

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: Two intramuscular injections
Study: NCT00047437

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise Training Program
Description: Exercise 30 minutes minimum three times per week.
Study: NCT03448809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind My Mind
Description: An individual, modular and flexible cognitive and behavioural therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU (Treatment as Usual)
Description: The children were offered anonymous counselling, supportive talk therapy, pedagogical advice, network meetings, and/or individual support in the school setting. A few were offered group-based CBT-programs for selected problems, but the access to manualized treatment was generally very restricted.